CVC Invests KRW 200 Billion in PharmaResearch to Accelerate Global Expansion
September 5, 2024
Global private equity firm CVC invested KRW 200 billion in South Korea's PharmaResearch via redeemable convertible preferred shares (RCPS). The minority growth investment will support PharmaResearch’s overseas market entry, strategic M&A activity, and R&D/product pipeline expansion in aesthetic injectables and regenerative medicines.
- Buyers
- CVC
- Targets
- PharmaResearch Co., Ltd.
- Industry
- Pharmaceuticals
- Location
- South Korea
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
1315 Capital Backs USpharma Ltd. with Growth Equity Investment
June 30, 2025
Pharmaceuticals
USpharma Ltd., a Miami Lakes-based pharmaceutical development and manufacturing company, received a growth equity investment from Philadelphia-based 1315 Capital. The capital will be used to accelerate development and commercialization of USpharma’s pipeline, expand commercial reach, and scale operations at its 150,000 sq. ft. US-based GMP facility.
-
CVC Capital Partners Acquires Majority Stake in Grupo GSH
April 16, 2025
Healthcare Services
CVC Capital Partners (Fund IX) will acquire a majority stake in Grupo GSH from Rede D’Or and Opus Investimentos, subject to regulatory approvals expected in Q3 2025. Grupo GSH, headquartered in Rio de Janeiro, is a leading Brazilian provider of hemotherapy (blood bank) and nuclear medicine/radiopharmacy services that serves hospitals and diagnostic centres across the country; CVC said it will support growth into new product categories and patient services.
-
KKR to Acquire Controlling Stake in Healthcare Global Enterprises (HCG) From CVC
February 24, 2025
Healthcare Services
KKR will acquire up to a 54% controlling stake in Healthcare Global Enterprises (HCG), India’s largest oncology hospital chain, from CVC Asia V through definitive agreements. Following the transaction and an SEBI-mandated open offer, KKR is expected to hold between 54% and 77% equity, with Dr. BS Ajai Kumar remaining as non-executive chairman.
-
SHS Capital and LPs Invest ~€10M in Develco Pharma
October 7, 2024
Pharmaceuticals
SHS Capital, together with its limited partners and other existing shareholders, is investing approximately €10 million in Develco Pharma to expand manufacturing capacity and accelerate product development in response to exceptionally strong demand. Develco, a specialty pharma developer and manufacturer of modified-release formulations headquartered in Pratteln (DACH region), has been backed by SHS since 2020 and reports an order book exceeding 12 months of revenue.
-
CVC Acquires Therakos Business from Mallinckrodt for $925M
August 5, 2024
Medical Devices
CVC Capital Partners Fund IX agreed to acquire the Therakos extracorporeal photopheresis business from Mallinckrodt plc for $925 million in a carve-out transaction. CVC said it will invest in further research, indication expansion and geographic growth of Therakos while key Therakos employees will transition with the business; Mallinckrodt will use proceeds to substantially reduce net debt.
-
CPS Capital Makes Growth Investment in PharmaSmart International
July 12, 2021
Medical Devices
Toronto-based private equity firm CPS Capital made a strategic growth investment in PharmaSmart International alongside the company’s existing management team. The financing (which included term debt from FirePower Capital and Nicola Wealth) will fund roll‑out of PharmaSmart’s PS-2000D health kiosk platform and accelerate expansion across Canada and the United States.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.